Dino Di Carlo
Dino Di Carlo received his B.S. in Bioengineering from the University of California, Berkeley in 2002 and received a Ph.D. in Bioengineering from the University of California, Berkeley and San Francisco in 2006. From 2006-2008 he conducted postdoctoral studies in the Center for Engineering in Medicine at Harvard Medical School. He has been on the faculty in the Department of Bioengineering at UCLA since 2008 and currently serves as the Vice Chair of the Department. He also serves as the Deputy Director of the National Science Foundation PATHS-UP Engineering Research Center, focusing on developing cost-effective technologies for diagnosing chronic diseases in underserved populations.
His research pioneered the use of inertial fluid dynamic effects for the control, separation, and analysis of cells in microfluidic devices. His recent work extends into numerous other fields including mechanomedicine, smart biomaterials, directed evolution of cells and quantum bioassays enabled by lab on a particle technologies.
He has also been a leader in technology entrepreneurship: He co-founded five companies that are commercializing UCLA intellectual property developed in his lab (CytoVale, Vortex Biosciences, Tempo Therapeutics, Forcyte, and Ferrologix).
Among other honors he received the Presidential Early Career Award for Scientists and Engineers (PECASE) and was elected a Fellow of the American Institute for Medical and Biological Engineering in 2016, He was elected a Fellow of the Royal Society of Chemistry (FRSC) in 2014, was awarded the National Science Foundation (NSF) Faculty Early Career Development award and the U.S. Office of Naval Research (ONR) Young Investigator Award, the Packard Fellowship and Defense Advanced Research Projects Agency (DARPA) Young Faculty Award, and received the National Institutes of Health (NIH) Director’s New Innovator Award and Coulter Translational Research Award.